Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...
Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.
Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...
The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy, are no longer in ...
HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...
Hims stock dropped sharply Friday after the U.S. Food and Drug Administration said the shortage of widely-used weight-loss ...
Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.
Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...